Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02301039 · ClinicalTrials.gov registry record · Phase 2
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
A Phase 2 study of Soft Tissue Sarcoma and Bone Sarcoma, sponsored by Sarcoma Alliance for Research through Collaboration.
- Completed
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
- 12
- Study locations
NCT02301039 is a Phase 2 study of Soft Tissue Sarcoma and Bone Sarcoma that has completed, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 144 participants, above the 76-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (89% higher). The trial reports 12 study locations across 10 states.
The verdict
NCT02301039, a Phase 2 study of Soft Tissue Sarcoma and Bone Sarcoma, has completed, sponsored by Sarcoma Alliance for Research through Collaboration.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to determine the efficacy of pembrolizumab in patients with advanced sarcomas.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (12)
Florida
- Mayo Clinic Florida - Jacksonville
- H. Lee Moffitt Cancer Center - Tampa
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
California
- University of Southern California - Los Angeles
District of Columbia
- Medstar Health Research Institute - Washington D.C.
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Mayo Clinic Cancer Center - Rochester
Missouri
- Washington University in St. Louis - St Louis
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2015-03 |
| Est. Completion | 2020-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02301039
The ClinicalTrials.gov registry entry for NCT02301039 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 76-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (89% higher). The listed sponsor is Sarcoma Alliance for Research through Collaboration, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02301039 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Florida, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT02301039 about?
NCT02301039 is a clinical study titled "SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas". The purpose of this study is to determine the efficacy of pembrolizumab in patients with advanced sarcomas.
What is the current status of trial NCT02301039?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2015-03. Estimated completion is 2020-07-01.
What conditions does trial NCT02301039 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma, Bone Sarcoma.
What interventions are being tested in trial NCT02301039?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02301039?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02301039 being conducted?
This trial has 12 study locations across California, District of Columbia, Florida, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
RECRUITING · Phase 2
-
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
RECRUITING · Phase 2
-
5-Day Preoperative Radiation for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.